Small molecule · Modulator of coagulation factor Xa (F10) · developed by Pfizer
ApprovedFDA, Dec 1994
1Registered trials
What is Dalteparin?
Dalteparin is a low molecular weight heparin that enhances antithrombin's inhibition of coagulation factor Xa and thrombin, with preferential action on factor Xa. It is studied in deep venous thrombosis and pulmonary embolism.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Fragmin
Drug type
Small molecule
Targets
antithrombin (SERPINC1) (binding partner it blocks), coagulation factor Xa (F10), thrombin (F2) (secondary target)
Mechanism
Modulator of coagulation factor Xa (F10)
Pathways
coagulation cascade, antithrombin-mediated inhibition of factor Xa and thrombin
Unstable angina and non-Q-wave myocardial infarction (prophylaxis of ischemic complications)
Deep vein thrombosis (prophylaxis)
Venous thromboembolism in adult patients with cancer (extended treatment)
Venous thromboembolism in pediatric patients (treatment to reduce recurrence)
From the indications section of the FDA label (version of Sep 30, 2025). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.